Rozanolixizumab effectively treats MuSK autoantibody-positive generalized myasthenia gravis, showing significant improvement in MG-ADL scores compared to placebo. MuSKgMG is more severe and ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for IgG4-related disease in April.

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. | On Thursday, the FDA green ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who ...

The FDA has approved Uplizna for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive.

Positive topline results from two phase 3 trials reported this week may expand the treatment landscape for generalized myasthenia gravis (gMG), a rare autoimmune disease marked by debilitating muscle ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin ...

The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or ...

SAN FRANCISCO -- Intravenous efgartigimod (Vyvgart) met its primary endpoint in adults with acetylcholine receptor (AChR) antibody-negative myasthenia gravis, the ADAPT SERON trial showed. At week 4, ...